Elahere (Mirvetuximab Soravtansine)

• Elahereis indicated as a treatment for adult patients with FRα-positive, platinum-resistant
• epithelial ovarian, fallopian tube, or primary peritoneal cancer. These patients should have
• received one to three prior systemic treatment regimens.
• The selection of patients for this therapy should be based on an FDA-approved test.
• Accelerated approval for this indication is based on tumor response rate and durability of
• response. Continued approval may be contingent upon verification and description of clinical
• benefit in a confirmatory trial.

Recommended Dosage:

• The recommended dose of Elahere is 6 mg/kg adjusted ideal body weight, given as an
• intravenous infusion every 3 weeks until disease progression or unacceptable toxicity.
• Patients should receive premedication with a corticosteroid, antihistamine, and antipyretic.
• Additionally, premedication with an antiemetic, ophthalmic topical steroids, and lubricating eye
• drops is recommended.
• Elahere should be administered as an intravenous infusion after dilution in 5% Dextrose Injection,
• USP, as it is not compatible with normal saline.

• Severe ocular toxicities, such as visual impairment, keratopathy, dry eye, photophobia, eye pain,
• and uveitis, can occur with Elahere.
• Ophthalmic examinations, including visual acuity and slit-lamp assessments, should be
• conducted before starting Elahere, every other cycle during the first 8 cycles, and as needed
• based on clinical judgment. Prophylactic artificial tears and ophthalmic topical steroids are
• recommended.
• Ocular toxicities should prompt a temporary suspension of Elahere until improvement, followed
• by resumption at the same or a reduced dose. Grade 4 ocular toxicities necessitate the
• discontinuation of Elahere.
• Pneumonitis: Elahere should be withheld if Grade 2 pneumonitis persists or recurs and dose
• reduction should be considered. Permanent discontinuation is advised for Grade 3 or 4
• pneumonitis.
• Peripheral Neuropathy: Patients should be closely monitored for new or worsening peripheral
• neuropathy. Dose adjustments or discontinuation of Elahere may be necessary depending on the
• severity of neuropathy.
• Embryo-Fetal Toxicity: Elahere carries a risk of fetal harm. Patients should be informed of the
• potential danger to a fetus and advised to use effective contraception.

If you are considering the import of Elahere (Mirvetuximab Soravtansine) to India, please be aware that Elahere can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
  
• Diagnostic reports of the patient.
  
• Government-issued identification proof for the patient, as recognized by the Government of India.

The order for Elahere will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
  
• An import permit, if applicable.

Elahere (Mirvetuximab Soravtansine) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Elahere can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Elahere (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Indian Pharma Network is proficient in sourcing Elahere (Mirvetuximab Soravtansine) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.

What is Elahere, and what is it used for?

Elahere is a medication that contains Mirvetuximab Soravtansine. It is primarily used for the treatment of a specific type of cancer known as epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is typically prescribed when the cancer has not responded to other treatments or has recurred.

How does Elahere work to treat cancer?

Elahere is an antibody-drug conjugate (ADC). It works by targeting cancer cells specifically. The antibody part of the drug attaches to a protein on the surface of cancer cells, delivering the chemotherapy drug (Soravtansine) directly to the cancer cells. This targeted approach can reduce damage to healthy cells.

 Are there any common side effects associated with Elahere?

Some common side effects of Elahere may include fatigue, nausea, vomiting, abdominal pain, and changes in blood counts. It’s important to discuss potential side effects with your healthcare provider and promptly report any adverse reactions.

 How is Elahere administered?

Elahere is typically administered as an intravenous (IV) infusion. Your healthcare provider will determine the dosage and the schedule of administration based on your specific medical condition.

 Is Elahere available in all regions, and how can I access it?

Elahere is a prescription medication and may not be readily available in all regions. Access to Elahere is typically facilitated by healthcare professionals and specialized pharmacies. To obtain Elahere, you will need a prescription from your doctor.